Oral Darolutamide presentation at ASCO on 31 May 2019

Impact of Darolutamide on Pain and Quality of Life in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) at ASCO taking place in Chicago.

Read more

Capital Markets Day 2019

Orion's Capital Markets Day was held on Wednesday 22 May 2019.

Read more

Half Year Report 2019

Orion will publish Half Year Report 2019 on Wednesday 17 July 2019 approximately at 12.00 (noon).

Financial Statements 2018

Published on 4 March 2019 I The Financial Statement documents 2018 include the Financial Statements, the Report of the Board of Directors and the Auditor’s Report.

Read more

Darolutamide submitted for marketing authorization also in Europe

8 Mar 2019 I Marketing authorization application has been submitted to EMA. The rolling submission to the FDA in the U.S. was recently completed and the application has also been submitted in the MHLW in Japan.

Read more

U.S. FDA accepts New Drug Application for review and grants Priority Review for darolutamide

Read more

Scientific article on ARAMIS study published in the New England Journal of Medicine

Read more

AGM 2019

The 2019 Annual General Meeting was held on 26 March 2019 in Helsinki. Read more here.

Read more

Stock Exchange Releases

6/11/2019 Change in Orion Corporation's holding of treasury shares
5/13/2019 Orion Corporation completed share acquisitions
5/13/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 13.05.2019
5/10/2019 ORION CORPORATION: ACQUISITION OF OWN SHARES 10.05.2019

Latest investor presentation

Press Releases

5/31/2019 2019 American Society of Clinical Oncology (ASCO) Annual Meeting - Darolutamide data presented
4/29/2019 U.S. FDA accepts New Drug Application for review and grants Priority Review for darolutamide
4/11/2019 Fire at Orion’s manufacturing plant in Turku
4/11/2019 Publishing of Orion Corporation's Interim Report for January-March 2019 on 25 April 2019

Share information

Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.

Read more

Major shareholders by votes

Monthly updated list of Orion's major shareholders by votes.

Read more

Orion's R&D Pipeline

Orion's key research projects include three ongoing Phase III trials, among others.

Read more
Research 

Orion Executive Management Board

The members of the Board of Directors

Orion included in FTSE4Good Index

Orion Corporation has been included in the globally recognised FTSE4Good Index.

Read more

Our approach to corporate responsibility
Orion's century
About Orion
Products and Services
Investors
Media
Corporate Governance
AGM
Sustainability
Contact us